- An Oxford University-led phase 2b trial demonstrated that oral live-attenuated vaccine CVD 1902 achieved 73% efficacy against Salmonella Paratyphi A infection in healthy adults. - The controlled human infection study enrolled 72 participants, with only 21% of vaccinated individuals developing infection compared to 75% in the placebo group. - This represents the first modern vaccine to show protection against paratyphoid fever, a disease affecting over 2 million people annually with no currently available vaccine. - The vaccine showed no safety concerns and only mild to moderate side effects, marking a significant step toward controlling enteric fever in resource-poor regions.

Oct 30, 2025

返回机构列表

Bharat Biotech International Ltd.

概览

试验阶段分布

试验状态分布

相关临床试验

该机构主办的试验（36）

Intranasal COVID-19 vaccine Phase 2 study in Healthy volunteers

A Phase II/III, Observer-blind, Multi-centre, RandomizedClinical Trial to Evaluate Immunogenicity and Safety of BBV87, anInactivated Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age

Intranasal Adenoviral vector COVID-19 vaccine (BBV154) Phase 1 study

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy, Safety, Immunogenicity,and Lot-to-Lot consistency of BBV152, a Whole virion Inactivated Vaccine in Adults greater than or equal to 18 Years of Age.

To evaluate the Immunogenicity and Safety of Inactivated Japanese encephalitis vaccine

to evaluate the Immunogenicity and Safety of Typbar-TCVÂ® in Adults

to determine the long term persistence of immune response of Typbar TCV

Typbar TCV 7 years followup - to determine the long term persistence of immune response of Typbar TCV

药物批准

按机构分类的批准

近期批准

资讯

Oxford Study Shows 73% Efficacy for First Paratyphoid A Vaccine Candidate